title: Economic evaluation of universal BCG vaccination of Japanese infants.
abstract: BACKGROUND
  The international controversy surrounding the use and effectiveness of the Bacillus Calmette-Guérin (BCG) vaccine and the low incidence of tuberculosis (TB) among Japanese children prompted this study.
  
  
  METHODS
  We compared 'universal BCG vaccination' with 'no vaccination at all' using a cost-effectiveness analysis. The study population was a hypothetical cohort comprising a total of 1.2 million infants born in 1996 at locations all over Japan. A model was developed to calculate the number of TB cases prevented by the vaccination programme. Assuming 40-80% overall vaccine efficacy (64-86% for TB-meningitis) and 10 years of protection, we calculated the cost and number of immunizations required to prevent one child from developing TB, the total number of TB cases averted by vaccination and total costs required for the programme.
  
  
  RESULTS
  Based on an assumption of flexible vaccine efficacy (40-80%), we estimated that 111-542 TB cases including 10-27 of TB-meningitis would be prevented during the 10 years after BCG vaccination among the cohort of infants born in 1996. About US$35 950-175 862 or 2125-10 399 immunizations would be required to prevent one child from developing TB. Sensitivity analyses covering a wide duration of protection, incidence of TB, vaccine coverage and discount rate, revealed that other than vaccine efficacy, the cost of preventing a single case of TB is highly sensitive to the duration of BCG protection and TB incidence.
  
  
  CONCLUSIONS
  The cost per case of TB prevented is heavily dependent on vaccine efficacy and the duration of protection, and is high compared with the cost of treating one child who has developed TB.
authors.affiliation: Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Rahman
authors.forename: M
authors.initials: M
authors.lastname: Sekimoto
authors.forename: I
authors.initials: I
authors.lastname: Takamatsu
authors.forename: K
authors.initials: K
authors.lastname: Hira
authors.forename: T
authors.initials: T
authors.lastname: Shimbo
authors.forename: K
authors.initials: K
authors.lastname: Toyoshima
authors.forename: T
authors.initials: T
authors.lastname: Fukui
mesh_terms: D001500:BCG Vaccine / Q000009:adverse effects / Q000191:economics*; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006285:Health Planning; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D007564:Japan / Q000453:epidemiology; D017059:Models, Econometric; D014376:Tuberculosis / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine